Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5AP | P20292 | 3/20 | 0.51 |
| ▸ | FEN1 | P39748 | 1/20 | 0.51 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.50 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.50 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.50 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.50 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.47 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.46 |
| ▸ | METAP2 | P50579 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4666689 | 1.00 | ALOX5AP (0.51) | ALOX5APFEN1CHRNB4CHRNA3CHRNB2 | |
| SCHEMBL9241908 | 1.00 | ALOX5AP (0.51) | ALOX5APFEN1CHRNB4CHRNA3CHRNB2 | |
| SCHEMBL2264753 | 0.89 | ALOX5AP (0.49) | ALOX5APFEN1CHRNB4CHRNA3 | |
| SCHEMBL8240624 | 0.87 | ALOX5AP (0.51) | ALOX5APFEN1CHRNB4CHRNA3CHRNB2 | |
| SCHEMBL13801184 | 0.87 | ALOX5AP (0.52) | ALOX5APFEN1CHRNB4CHRNA3CHRNB2 | |
| SCHEMBL8247133 | 0.87 | ALOX5AP (0.51) | ALOX5APFEN1CHRNB4CHRNA3CHRNB2 | |
| SCHEMBL938053 | 0.86 | ABHD6 (0.50) | ALOX5APFEN1CHRNB4CHRNA3CHRNB2 | |
| SCHEMBL938055 | 0.86 | ABHD6 (0.50) | ALOX5APFEN1CHRNB4CHRNA3CHRNB2 | |
| SCHEMBL27936838 | 0.86 | ABHD6 (0.50) | ALOX5APFEN1CHRNB4CHRNA3CHRNB2 | |
| SCHEMBL5152838 | 0.86 | CHRNB4 (0.49) | ALOX5APFEN1CHRNB4CHRNA3CHRNB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2649061-B1 | PYRIDINE AMIDE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS | Rottapharm Biotech Srl (IT) | 2015-05-13 | — | — | EP | disclosed |
| US-8828987-B2 | Pyridine amide derivatives as EP4 receptor antagonists | ROTTAPHARM BIOTECH S.R.L. (IT) | 2014-09-09 | — | — | US | disclosed |
| EP-2649061-A1 | PYRIDINE AMIDE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS | Rottapharm S.p.A. (IT) | 2013-10-16 | — | — | EP | disclosed |
| US-20130261100-A1 | PYRIDINE AMIDE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS | ROTTAPHARM BIOTECH S.R.L. (IT) | 2013-10-03 | — | — | US | disclosed |
| WO-2012076063-A1 | PYRIDINE AMIDE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS | ROTTAPHARM S.P.A. (IT) | 2012-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130261100-A1 | PYRIDINE AMIDE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS | PTGER4, PTGER1, CNR1 | ALOX5AP 322/4885FEN1 4773/4885CHRNB4 269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.